US5731324A — Glycoprotein IIb/IIIa antagonists

Claim 1

Independent Claim 199 words

A bicyclic compound having a nucleus formed from two fused six membered rings, A and B, represented by the formula (I), or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof: ##STR241## wherein: the bicyclic nucleus of rings A and B is formula (171) below: ##STR242## R 3 is an acidic group containing one or more acid radicals; n is a number from 0 to 6; R 0 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, or ═S; m is a number from 0 to 6; R 10 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, or ═S; with the proviso that only one R 10 may be ═O or ═S; linking group --(L)-- is a bond or a divalent substituted or unsubstituted chain of from 1 to 10 atoms selected from the group consisting of carbon, nitrogen, sulfur, and oxygen; and; Q is a basic group containing one or more basic radicals.

Claim 2

Dependent Claim 199 words

A bicyclic compound having a nucleus formed from two fused six membered rings, A and B, represented by the formula (I), or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof: ##STR241## wherein: the bicyclic nucleus of rings A and B is formula (171) below: ##STR242## R 3 is an acidic group containing one or more acid radicals; n is a number from 0 to 6; R 0 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, or ═S; m is a number from 0 to 6; R 10 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, or ═S; with the proviso that only one R 10 may be ═O or ═S; linking group --(L)-- is a bond or a divalent substituted or unsubstituted chain of from 1 to 10 atoms selected from the group consisting of carbon, nitrogen, sulfur, and oxygen; and; Q is a basic group containing one or more basic radicals.

Claim 3

Dependent Claim 21 words

A compound of claim 1 wherein the acid radicals of acidic group R 3 are selected from the following formulae: ##STR243##

Claim 4

Dependent Claim 18 words

The compound of claim 1 where the acid radicals in R 3 are selected from the group: ##STR244##

Claim 5

Dependent Claim 96 words

The compound of claim 1 wherein Q contains a basic radical selected from the group consisting of; amino, imino, amidino, N-alkylamidines, N,N'-dialkyamidines, N-arylamidines, aminomethyleneamino, iminomethylamino, guanidino, aminoguanidino, alkylamino, dialkylamino, trialkylamino, alkylideneamino, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolizinyl, isoindolyl, 3H-indolyl, indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, amide, thioamide, benzamidino, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbozolyl, carbozolyl, beta-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenarsazinyl, phenothiazinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, and any of the preceding groups substituted with amino, imino, amidino, aminomethyleneamino, iminomethylamino, guanidino, alkylamino, dialkylamino, trialkylamino, or alkylideneamino groups.

Claim 6

Dependent Claim 20 words

The compound of claim 4 wherein basic radical is selected from the group consisting of amino, piperidyl, guanidino, and amidino.

Claim 7

Dependent Claim 58 words

The compound of claim 1 wherein the linking group --(L)-- is selected from a group of from 1 to 4 chain atoms having the general formulae: ##STR245## where Z 1 , Z 2 , Z 3 , and Z 4 are atoms independently selected from the group consisting of carbon, substituted carbon, nitrogen, substituted nitrogen, sulfur, and oxygen.

Claim 8

Dependent Claim 15 words

The compound of claim 6 wherein the linking group is selected from the formulae; ##STR246##

Claim 9

Dependent Claim 32 words

A prodrug derivative compound selected from the group consisting of compounds represented by formulae (Xo) to (Xr) below: ##STR247## where, R=--H, --OMe, --OEt, --OPr, X=--Cl, --F, --H, R 15 =Me, Et, Pr.

Claim 10

Dependent Claim 32 words

A prodrug derivative compound selected from the group consisting of compounds represented by formulae (Xo) to (Xr) below: ##STR247## where, R=--H, --OMe, --OEt, --OPr, X=--Cl, --F, --H, R 15 =Me, Et, Pr.

Claim 11

Dependent Claim 292 words

A bicyclic compound or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof, having a nucleus formed from two fused six membered rings, represented by formula (Iaf) below: ##STR248## wherein; R 3 is an acidic group containing one or more acid radicals; n is a number from 0 to 6; R 0 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo, ═O or ═S; with the proviso that if R 0 is ═O or ═S, then only one of B 1 , B 2 , B 3 , and B 4 may be nitrogen; m is a number from 0 to 6; R 10 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, and ═S; with the proviso that only one R 10 may be ═O or ═S; t is a number from 0 to 3; R 20 is the same or different and is independently selected from hydrogen, halogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, carboxy, acyl, cyano, halo, nitro, sulfo; linking group --(L)-- is a bond or a divalent substituted or unsubstituted chain of from 1 to 10 atoms selected from the group consisting of carbon, nitrogen, sulfur, and oxygen; and; D is a ring formed from 5 to 8 ring atoms and said ring atoms are independently selected from carbon, nitrogen, oxygen, or sulfur, with the proviso that at least two D ring atoms are carbon; w is an integer from 1 to 3; and Q 1 is a basic radical.

Claim 12

Dependent Claim 292 words

A bicyclic compound or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof, having a nucleus formed from two fused six membered rings, represented by formula (Iaf) below: ##STR248## wherein; R 3 is an acidic group containing one or more acid radicals; n is a number from 0 to 6; R 0 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo, ═O or ═S; with the proviso that if R 0 is ═O or ═S, then only one of B 1 , B 2 , B 3 , and B 4 may be nitrogen; m is a number from 0 to 6; R 10 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, and ═S; with the proviso that only one R 10 may be ═O or ═S; t is a number from 0 to 3; R 20 is the same or different and is independently selected from hydrogen, halogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, aralkoxy, carboxy, acyl, cyano, halo, nitro, sulfo; linking group --(L)-- is a bond or a divalent substituted or unsubstituted chain of from 1 to 10 atoms selected from the group consisting of carbon, nitrogen, sulfur, and oxygen; and; D is a ring formed from 5 to 8 ring atoms and said ring atoms are independently selected from carbon, nitrogen, oxygen, or sulfur, with the proviso that at least two D ring atoms are carbon; w is an integer from 1 to 3; and Q 1 is a basic radical.

Claim 13

Dependent Claim 68 words

A compound of claim 9 wherein the D ring is formed from a nucleus selected from the group consisting of: benzene, cycloheptadiene, cycloheptatriene, cycloheptane, cyclohexane, cyclohexene, cyclohexadiene, cycloheptene, cyclooctadiene, cyclooctane, cyclooctatetraene, cyclooctene, cyclopentane, cyclopentene, imidazole, isooxazole, morpholine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrroline, tetrahydropyridine, tetrahydropyrimidine, 1H-tetrazole, thiazolidine, thiazole, thiopyran, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, dihydrofuran, dihydropyran, dioxane, dioxepin, dioxolane, furan, oxocane, tetrahydrofuran, tetrahydropyran, thiophene, and tetrahydrothiophene.

Claim 14

Dependent Claim 88 words

The compound of claim 9 wherein Q 1 is selected from the group consisting of amino, imino, amidino, aminomethyleneamino, iminomethylamino, guanidino, aminoguanidino, alkylamino, dialkylamino, trialkylamino, alkylideneamino, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolizinyl, isoindolyl, 3H-indoyl, indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, 4aH-carbozolyl, carbozolyl, beta-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenarsazinyl, phenothiazinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, and any of the preceding groups substituted with amino, imino, amidino, aminomethyleneamino, iminomethylamino, guanidino, alkylamino, dialkylamino, trialkylamino, or alkylideneamino groups.

Claim 15

Dependent Claim 19 words

The compound of claim 9 wherein basic radical in Q 1 is selected from amino, piperidyl, guanidino, and amidino.

Claim 16

Dependent Claim 28 words

A compound selected from the group consisting of compounds represented by the following formulae (VIII) to (VIIIi) or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof: ##STR249##

Claim 17

Dependent Claim 28 words

A compound selected from the group consisting of compounds represented by the following formulae (VIII) to (VIIIi) or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof: ##STR249##

Claim 18

Dependent Claim 31 words

A platelet aggregation inhibiting pharmaceutical formulation comprising: (i) a therapeutically effective platelet aggregation inhibiting amount of a bicyclic compound of claim 1; and (ii) a pharmaceutically acceptable carrier or diluent therefor.

Claim 19

Dependent Claim 31 words

A platelet aggregation inhibiting pharmaceutical formulation comprising: (i) a therapeutically effective platelet aggregation inhibiting amount of a bicyclic compound of claim 13; and (ii) a pharmaceutically acceptable carrier or diluent therefor.

Claim 20

Dependent Claim 31 words

A method for effecting inhibition of platelet aggregation which comprises administering to a mammal in need thereof an therapeutically effective platelet aggregation inhibiting amount of the bicyclic compound of claim 1.

Claim 21

Dependent Claim 31 words

A method for effecting inhibition of platelet aggregation which comprises administering to a mammal in need thereof an therapeutically effective platelet aggregation inhibiting amount of the bicyclic compound of claim 13.

Claim 22

Dependent Claim 17 words

A method of inhibiting fibrinogen binding by contacting glycoprotein IIb--IIIa sites with the compound of claim 1.

Claim 23

Dependent Claim 91 words

A method of treating a mammal to alleviate the pathological effects of atherosclerosis and arteriosclerosis, acute myocardial infraction, chronic stable angina, unstable angina, transient ischemic attacks and strokes, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism, restenosis following angioplasty, carotid endarterectomy, and anastomosis of vascular grafts; wherein the method comprises administering to said mammal at least one bicyclic compound of claim 1; wherein, said bicyclic compound is administered to said mammal in an amount sufficient to inhibit binding of fibrinogen on glycoprotein IIb-IIIa sites in said mammal to thereby inhibit said effects.

Claim 24

Dependent Claim 11 words

The method of claim 19 wherein the mammal is a human.

Claim 25

Dependent Claim 94 words

A method of treating a mammal to alleviate the pathological effects of atherosclerosis and arteriosclerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism, restenosis or abrupt closure following angioplasty, carotid endarterectomy, and anastomosis of vascular grafts; wherein the method comprises administering to said mammal at least one bicyclic compound of claim 13; wherein, said bicyclic compound is administered to said mammal in an amount sufficient to inhibit binding of fibrinogen on glycoprotein IIb-IIIa sites in said mammal to thereby inhibit said effects.

Claim 26

Dependent Claim 244 words

A bicyclic compound having a nucleus based on benzopyran as represented by the structural formula (IIIe): ##STR250## or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof, wherein; R 3 is an acidic group containing one or more acid radicals; n is a number from 0 to 6; R 0 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, arylalkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, or ═S; with the proviso that if R 0 is ═O or S, then only one of B 1 , B 2 , B 3 , and B 4 may be nitrogen; m is a number from 0 to 6; R 10 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, arylalkoxy, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, and ═S; with the proviso that only one R 10 may be ═O or ═S; linking group --(L)-- is a bond or a divalent substituted or unsubstituted chain of from 1 to 10 atoms selected from the group consisting of carbon, nitrogen, sulfur, or oxygen; and R 20 are the same or different and are independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, arylalkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, and sulfo; and p is an integer from 0 to 8.

Claim 27

Dependent Claim 244 words

A bicyclic compound having a nucleus based on benzopyran as represented by the structural formula (IIIe): ##STR250## or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof, wherein; R 3 is an acidic group containing one or more acid radicals; n is a number from 0 to 6; R 0 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, arylalkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, or ═S; with the proviso that if R 0 is ═O or S, then only one of B 1 , B 2 , B 3 , and B 4 may be nitrogen; m is a number from 0 to 6; R 10 is the same or different and is independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, arylalkoxy, carboxy, acyl, cyano, halo, nitro, sulfo, ═O, and ═S; with the proviso that only one R 10 may be ═O or ═S; linking group --(L)-- is a bond or a divalent substituted or unsubstituted chain of from 1 to 10 atoms selected from the group consisting of carbon, nitrogen, sulfur, or oxygen; and R 20 are the same or different and are independently selected from hydrogen, alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, arylalkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, and sulfo; and p is an integer from 0 to 8.

Claim 28

Dependent Claim 18 words

The compound represented by the formula (VIIId) or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof: ##STR251##

Claim 29

Dependent Claim 18 words

The compound represented by the formula (VIIId) or a pharmaceutically acceptable salt, solvate or prodrug derivative thereof: ##STR251##

Claim 30

Dependent Claim 20 words

A prodrug derivative compound represented by the formula (Xp) below: ##STR252## where X is --F and R 15 is ethyl.

Claim 31

Dependent Claim 20 words

A prodrug derivative compound represented by the formula (Xp) below: ##STR252## where X is --F and R 15 is ethyl.

Annuity Stage	Window Opens	Payment Deadline	Surcharge Period Until	Estimated Fee	Status
3.5 Years (Year 4)	2001-03-23	2001-09-22	2002-03-24	$2000.00	Window Closed / Lapsed
7.5 Years (Year 8)	2005-03-23	2005-09-22	2006-03-24	$3760.00	Window Closed / Lapsed
11.5 Years (Year 12)	2009-03-23	2009-09-22	2010-03-24	$7700.00	Window Closed / Lapsed

Glycoprotein IIb/IIIa antagonists

Abstract

Inventors

Bibliographic Details

Claims Analysis

References Cited (Backward Citations)

USPTO Annuity & Maintenance Windows

Assigned Categories & Tags

Assign Category Tag